Jeff Yass’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11M | Buy |
647,679
+126,214
| +24% | +$1.77M | ﹤0.01% | 3257 |
|
|
2026
Q1 | $6.69M | Sell |
521,465
-87,200
| -14% | -$1.11M | ﹤0.01% | 3747 |
|
|
2025
Q4 | $5.47M | Sell |
608,665
-281,696
| -32% | -$3.88M | ﹤0.01% | 3877 |
|
|
2025
Q3 | $15.4M | Buy |
890,361
+126,380
| +17% | +$1.56M | ﹤0.01% | 2486 |
|
|
2025
Q2 | $7.17M | Buy |
763,981
+334,876
| +78% | +$2.75M | ﹤0.01% | 3340 |
|
|
2025
Q1 | $3.05M | Sell |
429,105
-98,515
| -19% | -$995K | ﹤0.01% | 4610 |
|
|
2024
Q4 | $6.15M | Buy |
527,620
+110,569
| +27% | +$1.73M | ﹤0.01% | 3297 |
|
|
2024
Q3 | $8.57M | Buy |
417,051
+196,413
| +89% | +$4.53M | ﹤0.01% | 2823 |
|
|
2024
Q2 | $4.94M | Buy |
220,638
+121,114
| +122% | +$2.88M | ﹤0.01% | 3467 |
|
|
2024
Q1 | $2.74M | Sell |
99,524
-95,975
| -49% | -$2.67M | ﹤0.01% | 4687 |
|
|
2023
Q4 | $5.96M | Buy |
195,499
+87,710
| +81% | +$2.52M | ﹤0.01% | 3420 |
|
|
2023
Q3 | $3.41M | Sell |
107,789
-89,859
| -45% | -$3.49M | ﹤0.01% | 4168 |
|
|
2023
Q2 | $8.06M | Buy |
197,648
+54,046
| +38% | +$2.19M | ﹤0.01% | 2804 |
|
|
2023
Q1 | $5.35M | Buy |
143,602
+19,347
| +16% | +$759K | ﹤0.01% | 3369 |
|
|
2022
Q4 | $4.34M | Buy |
124,255
+9,129
| +8% | +$434K | ﹤0.01% | 3454 |
|
|
2022
Q3 | $6.44M | Buy |
115,126
+35,985
| +45% | +$2.23M | ﹤0.01% | 2773 |
|
|
2022
Q2 | $4.1M | Buy |
79,141
+18,862
| +31% | +$958K | ﹤0.01% | 3516 |
|
|
2022
Q1 | $4.38M | Buy |
60,279
+22,854
| +61% | +$1.94M | ﹤0.01% | 3863 |
|
|
2021
Q4 | $4.42M | Sell |
37,425
-47,776
| -56% | -$5.99M | ﹤0.01% | 3958 |
|
|
2021
Q3 | $11.4M | Buy |
85,201
+66,049
| +345% | +$10M | ﹤0.01% | 2675 |
|
|
2021
Q2 | $3.1M | Buy |
19,152
+4,227
| +28% | +$329K | ﹤0.01% | 4949 |
|
|
2021
Q1 | $1.2M | Sell |
14,925
-59,060
| -80% | -$3.96M | ﹤0.01% | 7243 |
|
|
2020
Q4 | $4.03M | Sell |
73,985
-71,253
| -49% | -$2.59M | ﹤0.01% | 3798 |
|
|
2020
Q3 | $2.89M | Buy |
145,238
+94,461
| +186% | +$1.97M | ﹤0.01% | 3931 |
|
|
2020
Q2 | $1.07M | Sell |
50,777
-36,103
| -42% | -$613K | ﹤0.01% | 5773 |
|
|
2020
Q1 | $1.06M | Buy |
86,880
+13,757
| +19% | +$185K | ﹤0.01% | 5272 |
|
|
2019
Q4 | $1.07M | Sell |
73,123
-2,525
| -3% | -$35.1K | ﹤0.01% | 5391 |
|
|
2019
Q3 | $1.01M | Sell |
75,648
-46,362
| -38% | -$739K | ﹤0.01% | 5663 |
|
|
2019
Q2 | $2M | Buy |
122,010
+108,901
| +831% | +$1.71M | ﹤0.01% | 4168 |
|
|
2019
Q1 | $224K | Sell |
13,109
-9,526
| -42% | -$142K | ﹤0.01% | 7714 |
|
|
2018
Q4 | $309K | Buy |
22,635
+10,792
| +91% | +$201K | ﹤0.01% | 6943 |
|
|
2018
Q3 | $339K | Buy |
+11,843
| New | +$345K | ﹤0.01% | 7236 |
|
|
2018
Q1 | – | Sell |
-24,093
| Closed | -$593K | – | 9897 |
|
|
2017
Q4 | $463K | Sell |
24,093
-18,585
| -44% | -$429K | ﹤0.01% | 6787 |
|
|
2017
Q3 | $1.06M | Buy |
+42,678
| New | +$804K | ﹤0.01% | 5159 |
|
|
2017
Q1 | – | Sell |
-36,415
| Closed | -$489K | – | 9641 |
|
|
2016
Q4 | $477K | Buy |
+36,415
| New | +$547K | ﹤0.01% | 7090 |
|
Other funds holding NTLA
AIM
RCM
RP
Jeff Yass's NTLA Position: Q2 2026 in Review
Jeff Yass increased its Intellia Therapeutics (NTLA) stake by 24% in Q2 2026, buying an estimated $1.77M and bringing the position to 647,679 shares worth $11M. The position accounts for ﹤0.01% of the portfolio, ranked #3257.
Jeff Yass first reported a position in NTLA in Q4 2016 and has held it in 35 quarters since. The position peaked at $15.4M in Q3 2025. 327 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.
- Jeff Yass held 647,679 shares of Intellia Therapeutics worth $11M as of Q2 2026.
- Jeff Yass bought 126,214 Intellia Therapeutics shares in Q2 2026, an estimated $1.77M.
- Intellia Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #3257 holding.
- Jeff Yass first reported a position in Intellia Therapeutics in Q4 2016 and has held it in 35 quarters since.
- Jeff Yass's Intellia Therapeutics position peaked at $15.4M in Q3 2025.
- 327 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.